The invention provides novel pharmaceutical compositions comprising as the
active ingredient 4-phenyl pinene derivatives which are specific for the
peripheral cannabinoid receptors. In particular, the compounds of the
invention binds efficiently to CB2 but do not bind to CB1. The compounds
show no activity in behavioral tests in mice which together have been
shown to be specific for tetrahydrocannabinol (THC)-type activity in the
central nervous system mediated by CB1 but reduce blood pressure, block
intestinal motility, and elicit anti-inflammatory and peripheral analgetic
activity. The invention also relates to methods of treating, preventing,
or managing hypertension, inflammation, pain, gastrointestinal diseases,
autoimmune diseases, and tumors with the compounds of the invention.
